BNB Token Treasury Company Windtree to Be Delisted From NASDAQ

The healthcare-focused firm will stop buying and selling its inventory on the NASDAQ by the top of the week, as its treasury technique has not yielded outcomes similar to these of its trade friends.

On an identical word, Technique’s inventory additionally skilled some jitters, albeit not as pronounced, attributable to different components.

Unlucky Flip Of Occasions

In a shock filing to the Securities and Change Fee (SEC), Windtree Therapeutics (ticker: WINT), an American drug growth firm for sufferers with respiratory illness, shall be delisted from the NASDAQ inventory market index for failing to adjust to its rules.

Particularly, it has failed to fulfill the requirement of a list rule, which states that any firm listed on the index should keep a minimal value of $1.00 per share. The corporate’s CEO, Jed Latkin, famous the next within the 8-Ok kind:

“On August 19, 2025, Windtree Therapeutics Inc. (the “Firm”) was notified by The Nasdaq Inventory Market LLC (“Nasdaq”) that because of the Firm’s beforehand disclosed noncompliance with Nasdaq Itemizing Rule 5550(a)(2).

Nasdaq has decided to delist the Firm’s widespread inventory from the Nasdaq Capital Market and, accordingly, will droop buying and selling within the Firm’s widespread inventory efficient on the open of buying and selling on August 21, 2025.”

It was simply over a month in the past that the agency announced it might be adopting the BNB coin as a part of a strategic reserve, with an preliminary funding of $60 million from Construct And Construct Corp. and a further $140M anticipated from additional subscriptions.

Throughout the identical month, the group sought a further $520 million in funding by way of a standard inventory buy settlement for a credit score line of as much as $500M, in addition to a separate $20 million inventory buy with Construct and Construct.

Information taken on the time of writing signifies that the corporate’s inventory has been falling closely for almost all of the yr, down over 97% during the last six months, with solely a slight enhance from $0.90 to $1.19 within the two days following the information that it had adopted a crypto treasury technique.

It’s unclear at this stage what spooked traders a lot, because the underlying asset of selection for the treasury has carried out exceptionally nicely this yr. On the time of printing, BNB is buying and selling at round $850, up 2.5% for the day and over 53% for the yr, based on knowledge from CoinMarketCap.

Is The Treasury Development Not Paying Off?

Windtree Therapeutics just isn’t the one treasury firm that has lately seen its inventory drop, because the Michael Saylor-founded Technique has additionally dwindled barely this week.

At present, the inventory is buying and selling round $344, down 9% over the previous 5 days, based on Google Finance. Nonetheless, that is nothing in comparison with the 143% enhance from final yr and the over 2,200% surge over the earlier 5 years.

The slight drop is probably going linked to Saylor’s post on X from Monday, when he disclosed that the corporate shall be altering its Fairness ATM (on the market) Steering, which meant that it’ll decrease the brink for promoting shares to fund extra bitcoin purchases.

Earlier than these adjustments, the agency’s coverage was to not subject new shares under 2.5 instances its market NAV (market worth divided by Bitcoin holdings), until it was strictly to cowl curiosity on debt or for dividend funds.

In distinction, now that the two.5 threshold has been decreased, shares will be issued at a decrease value, growing the pliability for company wants, but additionally making it riskier for shareholders.